[89Zr]ZrDFO-CR011 positron emission tomography correlates with response to glycoprotein non-metastatic melanoma B-targeted therapy in triple negative breast cancer
Lee S, Cavaliere A, Gallezot JD, Keler T, Michelhaugh SK, Belitzky E, Liu M, Mulnix T, Maher SE, Bothwell ALM, Li F, Phadke M, Mittal S, Marquez-Nostra B. [89Zr]ZrDFO-CR011 positron emission tomography correlates with response to glycoprotein non-metastatic melanoma B-targeted therapy in triple negative breast cancer. Molecular Cancer Therapeutics 2022, 21: molcanther.0590.2021. PMID: 35027482, PMCID: PMC8898259, DOI: 10.1158/1535-7163.mct-21-0590.Peer-Reviewed Original ResearchMeSH KeywordsGlycoproteinsHumansMelanomaMembrane GlycoproteinsPositron-Emission TomographyRadioisotopesTriple Negative Breast NeoplasmsZirconiumConceptsStandardized uptake valueTriple-negative breast cancerWeeks of treatmentCDX-011Tumor modelBreast cancerMelanoma BPretreatment standardized uptake valueAntibody-drug conjugate (ADC) therapyPatient-derived tumor modelsNegative breast cancerSingle bolus injectionPositron emission tomographyTumor regrewPretreatment PETADC therapyPrognostic markerBolus injectionTumor volumeSUV ratioRadiotracer uptakeUptake valueStrong inverse correlationTumor typesPercent change